US · Healthcare · Biotechnology
EPS came in at -1.43 against a street estimate of 1.42 — a miss of 200.7%.
Analysts rate Ligand Pharmaceuticals Incorporated a strong buy (11 buy, 0 hold, 0 sell out of 11) with an average price target of $350.92.
CONFIDENT Ligand reported strong royalty growth, raised adjusted EPS guidance, and highlighted major portfolio expansion through XOMA, while fourth-quarter timing and clinical outcomes remain key uncertainties. Q3 FY26 The portfolio spans more than 200 commercial, clinical and preclinical royalty assets, with up to seven pivotal readouts anticipated through 2027. Analysts focused on XOMA’s hidden assets, future capital deployment, QTORIN’s commercial opportunity, guidance conservatism, synergies and risk-adjusted returns. Management emphasized unchanged XOMA accretion, better cost synergies, disciplined investing and substantial pipeline optionality. 2026-10-29…
Full summary in the app.
| Fund | Stake |
|---|---|
| BlackRock Inc | 15.56% |
| Amvescap Plc. | 6.03% |
| Vanguard Portfolio Management, LLC | 5.71% |
| Jupiter Topco LLC | 5.22% |
| Vanguard Capital Management, LLC | 4.37% |
| State Street Corp | 4.15% |
| FMR Inc | 3.83% |
| Franklin Templeton Inc | 3.77% |
| Document | Date |
|---|---|
| Quarterly report · Q3 2026 HEADLINE NUMBERS • Q3 2026 total revenues and income were $78.746 million, down from $115.461 million in Q3 2025. • Q3 2026 net loss was $28.485 mi | 2026-10-30 |
| Results announced · Q4 2026 HEADLINE NUMBERS • Third-quarter 2026 royalty revenue increased 51% year over year to $70.3 million, from $46.6 million. • Total revenues and income | 2026-10-29 |
| Reg FD disclosure · Q3 2026 LIGAND PHARMACEUTICALS INC - FORM 8-K SUMMARY HEADLINE NUMBERS • Ligand Pharmaceuticals entered into a financing agreement with AvenCell Therapeutic | 2026-09-24 |
| Reg FD disclosure · Q3 2026 LIGAND PHARMACEUTICALS INC - FORM 8-K SUMMARY HEADLINE NUMBERS • Ligand acquired royalty and milestone payment rights relating to Santen Pharmaceuti | 2026-09-22 |
| Quarterly report · Q2 2026 LIGAND PHARMACEUTICALS INCORPORATED – Q2 2026 10-Q SUMMARY HEADLINE NUMBERS • Cash and cash equivalents: $1,006.7 million at June 30, 2026, up from | 2026-08-07 |
| Results announced · Q3 2026 LIGAND PHARMACEUTICALS Q2 2026 EARNINGS SUMMARY HEADLINE NUMBERS • Q2 2026 Total Revenue: $63.7 million vs. $47.6 million in Q2 2025 (34% increase) | 2026-08-06 |
| Material agreement · Q3 2026 LIGAND PHARMACEUTICALS - 8-K SUMMARY (July 14, 2026) HEADLINE NUMBERS • Merger completed July 14, 2026: Ligand acquired XOMA Royalty Corporation thr | 2026-07-14 |
| Material agreement · Q2 2026 LIGAND PHARMACEUTICALS INCORPORATED – 8-K SUMMARY HEADLINE NUMBERS • Completed private offering of $700.0 million aggregate principal amount of 0.00 | 2026-06-25 |
Readable in the app.
| Announcement | Date |
|---|---|
| Entry into financing agreement with clinical-stage cell therapy company Ligand Pharmaceuticals announced on September 24, 2026 that it entered into a financing agreement with AvenCell Therapeutics, a clinical-stage company developing controllable, allogeneic CAR | 2026-09-24 |
| Acquired royalty and milestone payment rights relating to Ryjunea Ligand Pharmaceuticals announced on September 22, 2026, that it acquired royalty and milestone payment rights related to Santen Pharmaceutical's Ryjunea® from Sydnexis, Inc. for $23 million | 2026-09-22 |
| Company completes merger with HoldCo; shareholders receive cash and contingent value rights On July 14, 2026, XOMA Royalty completed a merger with a holding company (HoldCo). Here's what happened: MERGER TERMS: Each shareholder received $39 per share in cash plus contingent value | 2026-07-14 |
| Entered into merger agreement with XOMA Royalty Corporation Ligand Pharmaceuticals amended its merger agreement with XOMA Royalty Corporation on May 16, 2026. The amendment adds XOMA Royalty Holdings Corporation (HoldCo), a newly formed Nevada holdin | 2026-05-18 |
| Entered into Agreement and Plan of Merger with XOMA Royalty Corporation Ligand Pharmaceuticals agreed to acquire XOMA Royalty Corporation in an all-cash merger deal announced April 27, 2026. XOMA Royalty shareholders will receive $39 per share in cash plus conti | 2026-04-27 |
Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for Ligand Pharmaceuticals Incorporated — free to start.
Open in the appGoogle PlayApp StoreData updated 2026-11-07.